The proposed neratinib dosage regimen is 240 mg (40 mg × 6 tablets) given orally once daily (QD) with food, continuously for one year. Diarrhea was the main dose-limiting toxicity (DLT). The prophylactic use of loperamide is recommended along with the first dose of neratinib and maintained regularly during the first 1-2 months. The efficacy and safety of neratinib for the application was based on an international, randomized, double-blind, Phase 3 trial of neratinib versus placebo in women with early-stage ERBB2-positive breast cancer following standard locoregional treatment, chemotherapy, and adjuvant treatment with trastuzumab for 12 months (Study 3144A2-3004-WW).